Tinzaparin is safe and effective in the management of hemodialysis catheter thrombosis

ASAIO Journal

Volumn 58, Issue 3, 2012, Pages 288-290

  Quinlan, Catherine ^a   Bates, Marie ^a   Cotter, Melanie ^a   Riordan, Michael ^a   Waldron, Mary ^b   Awan, Atif ^a  

^a CHILDREN S UNIVERSITY HOSPITAL   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

HEMODIALYSIS CATHETER; IRELAND; NORMAL FLOW; TREATMENT WELLS;

BLOOD VESSELS; CATHETERS; DISEASES; HEMODIALYZERS;

DIALYSIS;

FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ADOLESCENT; ARTICLE; CENTRAL VENOUS CATHETERIZATION; CHILD; DRUG MONITORING; HUMAN; INFANT; PRESCHOOL CHILD; RENAL REPLACEMENT THERAPY; THROMBOSIS;

ADOLESCENT; CATHETERIZATION, CENTRAL VENOUS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT; RENAL DIALYSIS; THROMBOSIS;

EID: 84860717382     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAT.0b013e31824c38c8     Document Type: Article

References (8)

1. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association: Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant 17 (Suppl 7): 63-71, 2002.
2. Malo J, Jolicoeur C, Theriault F, Lachaine J, Senecal L: Comparison between standard heparin and tinzaparin for haemodialysis catheter lock. ASAIO J 56: 42-47, 2010.
3. Monagle P, Chalmers E, Chan A, et al; American College of Chest Physicians: Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl): 887S- 968S, 2008.
4. Van Biljon I, Van Damme-Lombaerts R, Demol A, Van Geet C, Proesmans W, Arnout J: Low molecular weight heparin for anticoagulation during haemodialysis in children-a preliminary study. Eur J Pediatr 155: 70, 1996.
5. Bianchetti MG, Speck S, Muller R, Oetliker OH: Simple coagulation prophylaxis using low-molecular heparin enoxaparin in pediatric hemodialysis. Schweiz Rundsch Med Prax 79: 730-731, 1990.
6. Kuhle S, Massicotte P, Dinyari M, et al: Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 94: 1164-1171, 2005.
7. Lim W, Dentali F, Eikelboom JW, Crowther MA: Meta-analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144: 673-684, 2006.
8. Siguret V, Gouin-Thibault I, Pautas E, Leizorovicz A: No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: The IRIS substudy. J Thromb Haemost 9: 1966-1972, 2011.